175 related articles for article (PubMed ID: 35972603)
1. Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide.
Ozgiray E; Sogutlu F; Biray Avci C
Med Oncol; 2022 Aug; 39(11):166. PubMed ID: 35972603
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
Chen Y; Tseng BJ; Tsai YH; Tseng SH
Anticancer Res; 2020 Sep; 40(9):5141-5149. PubMed ID: 32878802
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
5. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
7. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
8. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
[TBL] [Abstract][Full Text] [Related]
9. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
10. FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
He C; Lu S; Wang XZ; Wang CC; Wang L; Liang SP; Luo TF; Wang ZC; Piao MH; Chi GF; Ge PF
Acta Pharmacol Sin; 2021 Aug; 42(8):1324-1337. PubMed ID: 33879840
[TBL] [Abstract][Full Text] [Related]
11. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
12. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Hayashi T; Adachi K; Ohba S; Hirose Y
J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
14. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
15. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Ohba S; Hirose Y; Kawase T; Sano H
J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
[TBL] [Abstract][Full Text] [Related]
18. Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
Schaff LR; Kushnirsky M; Lin AL; Nandakumar S; Grommes C; Miller AM; Gavrilovic IT; Nolan C; Pentsova E; Mellinghoff IK; Kaley TJ
Neurology; 2022 Oct; 99(17):750-755. PubMed ID: 35948444
[TBL] [Abstract][Full Text] [Related]
19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
20. Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Shao N; Mao J; Xue L; Wang R; Zhi F; Lan Q
J Neurooncol; 2019 Jan; 141(2):277-288. PubMed ID: 30460630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
